9.15 on the NASDAQ. This SniperIQ fundamentals page covers Immunovant's valuation, profitability (net margin 0.0%), balance-sheet quality, and AI signal context — from live market data, research only.

Market Cap$8.0B
Net Margin0.0%

Full research coverage

Frequently Asked Questions

What is Immunovant's market cap?

Immunovant (IMVT) has a market capitalization of approximately $8.0B, trading at

9.15 on the NASDAQ. Market cap moves with the live share price.

What is Immunovant's P/E ratio?

Immunovant's trailing twelve-month P/E ratio is not meaningful (negative or nil earnings), with a price-to-book (P/B) of 9.4x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.

How profitable is Immunovant?

Immunovant runs a net profit margin of 0.0%, a gross margin of 0.0%, and an operating margin of 0.0%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.

Does Immunovant pay a dividend?

Immunovant does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.

Is Immunovant financially healthy?

Immunovant carries a debt-to-equity ratio of 0.00x and a current ratio of 9.09x, with a market beta of 0.77. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.

Is Immunovant a good stock to buy in 2026?

SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Immunovant (IMVT) the key facts are: market cap $8.0B, 52-week range 14.32-41.23. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.

Track Immunovant's full fundamentals live

Get Immunovant's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.